Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
First-in-human trial initiations reveal four KRAS assets.
For $850m up front Roche gets to challenge Pfizer.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.